Effects of toremifene versus tamoxifen on breast cancer patients: A meta-analysis

Breast Cancer

Volumn 20, Issue 2, 2013, Pages 111-122

  Chi, Feng ^a   Wu, Rong ^a   Zeng, Yuecan ^a   Xing, Rui ^a   Liu, Yang ^a   Xu, Zhaoguo ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Breast neoplasm; Meta analysis; Tamoxifen; Toremifene

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TAMOXIFEN; TOREMIFENE; TRIACYLGLYCEROL; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

BONE DENSITY; BREAST CANCER; CANCER SURVIVAL; CHOLESTEROL BLOOD LEVEL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; HEART DISEASE; HOT FLUSH; HUMAN; INTRAOCULAR HEMORRHAGE; MEDICAL DECISION MAKING; META ANALYSIS; METHODOLOGY; NAUSEA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY CONTROL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SWEATING; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TRIACYLGLYCEROL BLOOD LEVEL; VAGINA BLEEDING; VAGINA DISCHARGE; VOMITING; ARTICLE; BREAST TUMOR; COMPARATIVE STUDY; FEMALE; META ANALYSIS (TOPIC); PROGNOSIS;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; FEMALE; HUMANS; META-ANALYSIS AS TOPIC; PROGNOSIS; TAMOXIFEN; TOREMIFENE;

EID: 84884754890     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/s12282-012-0430-6     Document Type: Review

References (41)

1. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998;339(22):1609-18. (Pubitemid 28536137)
2. EBCTCG. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687-717.
3. Marttunen MB, Hietanen P, Tiitinen A, et al. Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients. J Clin Endocrinol Metab. 1998;83:1158-62. (Pubitemid 28496385)
4. Bao T, Davidson NE. Adjuvant endocrine therapy for premenopausal women with early breast cancer. Breast Cancer Res. 2007;9(6):115.
5. Kallio S, Kangas L, Blanco G, et al. A new triphenylethylene compound, Fc-1157a. I. Hormonal effects. Cancer Chemother Pharmacol. 1986;17(2):103-8. (Pubitemid 16082005)
6. Marttunen MB, Cacciatore B, Hietanen P, et al. Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women. Br J Cancer. 2001;84(7):897-902. (Pubitemid 32385831)
7. Gershanovich M, Garin A, Baltina D, et al. A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer. Eastern European Study Group. Breast Cancer Res Treat. 1997;45(3):251-62. (Pubitemid 27453794)
8. Hayes DF, Van Zyl JA, Hacking A, et al. Randomised comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol. 1995;13:2556-66.
9. Holli K, Valavaara R, Blanco G, et al. Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group. J Clin Oncol. 2000;18(20):3487-94.
10. Pyrhönen S, Valavaara R, Modig H, et al. Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the 'Nordic' phase III study. Br J Cancer. 1997;76:270-7.
11. Hirsimaki P, Aaltonen A, Mantyla E. Toxicity of antiestrogens. Breast J. 2002;8(2):92-6. (Pubitemid 34233587)
12. Mao C, Yang Z-Y, He B-F, et al. Toremifene versus tamoxifen for advanced breast cancer. Cochrane Database Syst Rev. 2012;. doi: 10.1002/14651858. CD008926.pub2.
13. Pyrhonen S, Ellmen J, Vuorinen J, et al. Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer. Breast Cancer Res Treat. 1999;56(2):133-43. (Pubitemid 29494831)
14. Zhou WB, Ding Q, Chen L, et al. Toremifene is an effective and safe alternative to tamoxifen in adjuvant endocrine therapy for breast cancer: results of four randomized trials. Breast Cancer Res Treat. 2011;128(3):625-31.
15. Higgins JPT, Green SJ. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 (updated September 2009). The Cochrane Collaboration. http://www.Cochrane-handbook.org. 2009.
16. Schunemann HJ, Jaeschke R, Cook DJ, et al. An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. Am J Respir Crit Care Med. 2006;174(5):605-14. (Pubitemid 44330555)
17. DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials. 2007;28(2):105-14. (Pubitemid 44937874)
18. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-88. (Pubitemid 17189972)
19. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997;127(9):820-6. (Pubitemid 27465551)
20. Marttunen MB, Hietanen P, Titinen A, et al. Effects of tamoxifen and toremifene on urinary excretion of pyridinoline and deoxypyridinoline and bone density in postmenopausal patients with breast cancer. Calcif Tissue Int. 1999;65(5):365-8. (Pubitemid 29514073)
21. Tiitinen A, Nikander E, Hietanen P, et al. Changes in bone mineral density during and after 3 years' use of tamoxifen or toremifene. Maturitas. 2004;48(3):321-7. (Pubitemid 38781157)
22. Gylling H, Pyrhonen S, Mantyla E, et al. Tamoxifen and toremifene lower serum cholesterol by inhibition of delta 8-cholesterol conversion to lathosterol in women with breast cancer. J Clin Oncol. 1995;13(12):2900-5.
23. Joensuu H, Holli K, Oksanen H, et al. Serum lipid levels during and after adjuvant toremifene or tamoxifen therapy for breast cancer. Breast Cancer Res Treat. 2000;63(3):225-34.
24. Saarto T, Blomqvist C, Ehnholm C, et al. Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. J Clin Oncol. 1996;14(2):429-33. (Pubitemid 26051003)
25. Tominaga T, Kimijima I, Kimura M, et al. Effects of toremifene and tamoxifen on lipid profiles in post-menopausal patients with early breast cancer: interim results from a Japanese phase III trial. Jpn J Clin Oncol. 2010;40(7):627-33.
26. Ha HK, Han W, Ko E, et al. Toremifene as an adjuvant hormone therapy for estrogen receptor positive early breast cancer: therapeutic efficacy and effect on endometrium. J Breast Cancer. 2007;10(4):258-62.
27. Tomas E, Kauppila A, Blanco G, et al. Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients. Gynecol Oncol. 1995;59(2):261-6.
28. Ellmen J, Hakulinen P, Partanen A, et al. Estrogenic effects of toremifene and tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res Treat. 2003;82(2):103-11. (Pubitemid 37476010)
29. Milla-Santos A, Milla L, Rallo L, et al. Phase III randomized trial of toremifene vs tamoxifen in hormonodependant advanced breast cancer. Breast Cancer Res Treat. 2001;65:119-24. (Pubitemid 32193615)
30. Nomura Y, Tominaga T, Abe O, et al. Clinical evaluation of NK 622 (toremifene citrate) in advanced or recurrent breast cancer - a comparative study by a double blind method with tamoxifen. Gan To Kagaku Ryoho. 1993;20(2):247-58. (Pubitemid 23108971)
31. Stenbygaard LE, Herrstedt J, Thomsen JF, et al. Toremifene and tamoxifen in advanced breast cancer - a double-blind cross-over trial. Breast Cancer Res Treat. 1993;25(1):57-63. (Pubitemid 23107736)
32. Gianni L, Panzini I, Li S, et al. Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trials. Cancer. 2006;106(3):505-13. (Pubitemid 43157612)
33. Pagani O, Gelber S, Simoncini E, et al. Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group trials 12-93 and 14-93. Ann Oncol. 2004;15(12):1749-58. (Pubitemid 40012241)
34. Lewis JD, Chagpar AB, Shaughnessy EA, et al. Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer. Cancer. 2010;116:2307-15.
35. Lu Q. Tamoxifen and toremifene in the treatment of recurrent or metastatic breast cancer: a comparative study. Contemp Med. 2011;17(26):128-9.
36. Tian LJ, Xu BH. Comparative study of the effects of toremifene and tamoxifen on blood lipid levels in breast cancer. Pract J Cancer. 2004;19(5):520-2.
37. Kusama M, Miyauchi K, Aoyama H, et al. Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer. Breast Cancer Res Treat. 2004;88(1):1-8. (Pubitemid 39524439)
38. Homesley HD, Shemano I, Gams RA, et al. Antiestrogenic potency of toremifene and tamoxifen in postmenopausal women. Am J Clin Oncol. 1993;16(2):117-22. (Pubitemid 23109718)
39. Ochi J, Hayakawa K, Moriguchi Y, et al. Uterine changes during tamoxifen, toremifene, and other therapy for breast cancer: evaluation with magnetic resonance imaging. Jpn J Radiol. 2010;28(6):430-6.
40. Esteva FJ, Hortobagyi GN. Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women. Breast. 2006;15(3):301-12. (Pubitemid 43812225)
41. Jordan VC, Gapstur S, Morrow M. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease. J Natl Cancer Inst. 2001;93(19):1449-57. (Pubitemid 32982673)